Pancreatic adenocarcinoma is one of the most lethal cancers in oncology. Pancreatic cancer
is the third most common cause of cancer-related mortality in the United States. As the years …

Borderline resectable pancreatic cancer (BRPC) has emerged as a unique entity among the
spectrum of pancreatic cancer adenocarcinoma. BRPC is defined as pancreatic cancer …

Pancreatic cancer is the fourth most common cause of cancer death in the United States.
Surgery remains the only curative option; however only 20% of the patients have resectable …

Background Patients with borderline resectable pancreatic cancer are at high risk of having
positive surgical margins due to involvement of the tumor with adjacent vasculature. This …

Adenocarcinoma of the pancreas remains a highly lethal disease, with less than 5% survival
at 5 years. Borderline resectable pancreatic cancer (BRPC) and locally advanced …

Patients with borderline resectable pancreatic adenocarcinoma have primary tumors within
the pancreas that involve the mesenteric vasculature to a limited degree. Their tumors are …

Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death
among US men and women. Despite much effort in translational research, pancreatic …

Background Borderline resectable pancreatic cancer constitutes a complex clinical entity,
presenting the clinician with a locally aggressive disease that has a proclivity for distant …

With the rapid development of imaging modalities and surgical techniques, the clinical entity
representing tumors that are intermediate between resectable and unresectable pancreatic …

Historically, borderline resectable (BLR) pancreatic cancer has had many definitions, which
has made interpretation of treatment data and outcomes difficult. Advances in imaging …